Background: Smoking is known as the major cause of chronic obstructive pulmonary disease (COPD). In COPD, most of pulmonary function tests (PFTs) those indicating the diameter of airways are reduced. There are reports that bronchodilator drugs have no or a very little effect on PFT of COPD patients.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity throughout the world. Many people suffer from this disease for years and die prematurely from it or its complications. COPD is currently the fourth leading cause of death in the world [1] , and further increases in its prevalence and mortality can be predicted in the coming decades [2] . Cigarette smoking is by far the most important risk factor for COPD and the most important way that tobacco contributes to the risk of COPD. [3] Cigarette smokers have a higher prevalence of respiratory symptoms, pulmonary function abnormalities, greater annual rate of decline in FEV1, and a greater COPD mortality rate than those of non-smokers. [4] These differences between cigarette smokers and non-smokers increase in direct proportion to the quantity of smoking. Smoking leads to rapid decline in pulmonary function tests (PFTs) specially those indicating diameter of airways such as forced expiratory flow in one second (FEV1). [5] Even in teenagers who have smoked only a few years, maximum expiratory flow volume curves demonstrate decreases in flow rates at small lung volumes [6] yet another expression of small airway obstruction. If smoking causes changes in small airway calibre at such an early age, one might expect that smoking also causes acute changes in these small airways. Until now, the only well documented acute effect of smoking on the airways was the decrease of airway conductance demonstrated by Nadel and Comroe. [7] The obstruction to airflow that develops in 15 to 20% of heavy smokers is thought to be due to abnormalities in airways with less than 2 mm internal diameter. [8] Previous studies from several laboratories have shown that this airway obstruction is associated with chronic inflammatory process in the membranous and respiratory bronchioles. [9, 10] It is believed that the airway constriction in COPD and decline in PFT are not reversible. Therefore, in the present study the pulmonary function tests of smokers were compared with those of nonsmokers. The effect of quantity and duration of smoking on PFT and the reversibility of PFT were also evaluated in the present study.
MATERIALS AND METHODS
Expiratory flow-volume curves were recorded by a spirometer with a pneumotachograph sensor (Model ST90, Fukuda Sangyo Co. Ltd. Japan). The spirometer was calibrated daily for few days at the beginning, end and, a few intervals during the middle of the study with a three-litre calibrating syringe. However, because there were almost no differences in daily calibrations, calibration of the spirometer was carried out weekly in the rest of the study. Prior to testing, the required maneuver was demonstrated by the operator, and subjects were encouraged and supervised throughout the test performance. Studies were performed using the acceptability standards outlined by the "American Thoracic Society" (ATS) with subjects in a standing position and wearing nose clips. [11] In 30 smokers, PFTs were repeated 10 min after 200 μg inhaled salbutamol. Pulmonary function tests were performed three times in each subject with an acceptable technique. The highest levels for forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximal midexpiratory flow (MMEF), peak expiratory flow (PEF), and maximal expiratory flow at 75%, 50%, and 25% of the FVC (MEF75, MEF50, and MEF25 respectively) were taken independently from the three curves.
Data Analysis
The data of height, age, and pulmonary function parameters were expressed as mean ± SD. PFTs of smokers were compared with those of nonsmokers using unpaired t-test. PFTs obtained after inhaled salbutamol were compared with the baseline values using paired t-test. The duration and quantity of smoking were related to decrease in their PFT values, using the least square regression. The criterion of significance was p<0.05.
RESULTS

Duration and Quantity of Smoking
Mean duration of smoking was 17.41 ± 4.68 years (range 2-50 years) and mean quantity of smoking was 12.09 ± 9.68 Cigarettes per day (range 0.25-50). 
Pulmonary Function Tests
All values of pulmonary function tests in smokers were significantly lower than those of nonsmoker subjects (p<0.02 to P<0.001) except MEF25. There was significant negative correlation between duration of smoking and decrease in FEV1, PEF, MEF75, and MEF50 (p<0.05 to p<0.01). However, the correlations between the quantity of smoking and values of PFT were not significant.
Low PFTs among Smoker and Nonsmoker Subjects
The percentage of low values of most PFTs (lower than 80% predictive values) among smoker was significantly more than those of normal subjects (Table 3 ). Only 0-10.6% of nonsmokers had low PFT values while in 21.6-42.3% of smokers PFT values were lower than normal range. The results of the present study also showed negative correlation between decrease in most values of PFT and duration of smoking. However, the relationships between decrease in PFTs and quantities of smoking were not significant. These results showed that duration of smoking has more profound effect on airways than quantity of smoking. 
Effect of Salbutamol on PFTs of Smokers
CONCLUSION
The results of our study demonstrated a relatively large component of reversibility of airways in smokers, which is a novel finding of the present study. In conclusion, the results of the present study demonstrated the profound effect of smoking on PFT and, therefore, indicated that smoking leads to constriction of large and medium airways, which is mostly due to duration, not to quantity of smoking. The airway constriction in smokers was reversible which was mostly seen for medium and small sized airways.
